You are here

Merck KGaA

Big pharma holds steady on research spending

EP Vantage

Fri, 04/21/23 - 10:03 am

Merck KGaA's multiple sclerosis drug hit with partial FDA hold, adding to BTK-liver injury links

Fierce Biotech

Wed, 04/12/23 - 11:52 am

multiple sclerosis

Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends

Endpoints

Mon, 03/27/23 - 10:04 pm

Merck KGaA makes its Foundry data tools available for free

Pharmaphorum

Wed, 03/8/23 - 09:40 am

Palantir Technologies

Foundry DevTools

Merck KGaA, Haleon warn of more inflation challenges in 2023

Fierce Pharma

Thu, 03/2/23 - 10:04 am

Merck KGaA, spying a major market, pays Aqilion €10M to tackle tough autoimmune target

Fierce Biotech

Thu, 02/16/23 - 10:26 am

autoimmune disease

Layoffs continue to batter biotech, with Big Pharmas piling on the pain

Fierce Biotech

Wed, 02/1/23 - 10:32 pm

TCR2 Therapeutics

Moderna Therapeutics

Merck KGaA shrinks U.S. research team as layoffs continue to batter industry

Fierce Biotech

Mon, 01/23/23 - 10:48 am

Merck KGaA hands over IL-12-targeting cancer med to PDS Biotech in $121M deal

Fierce Biotech

Tue, 01/3/23 - 10:26 pm

PDS Biotechnology

Vera finally notches a win for Merck KGaA castoff in autoimmune kidney disease

Fierce Biotech

Tue, 01/3/23 - 10:21 pm

Vera Therapeutics

autoimmune kidney disease

Merck KGaA outlines plan to rev up drug R&D

BioPharma Dive

Mon, 11/21/22 - 06:36 pm

drug development

Merck KGaA’s MilliporeSigma invests $286M to build out biosafety testing

Endpoints

Wed, 11/16/22 - 11:19 pm

biosafety testing

CEOs of BioNTech, Bayer, Merck KGaA join German Chancellor Scholz in high-profile China visit

Fierce Pharma

Sun, 11/6/22 - 01:36 pm

Systemic lupus erythematosus: major drug trials to watch in 2022 and 2023

Clinical Trials Arena

Mon, 10/31/22 - 10:37 am

clinical trials

systemic lupus erythematosus

Swedish Orphan Biovitrum

Pfizer, Merck and J&J Back UK Startup Mining the Dark Genome for Autoimmune Therapies

BioSpace

Wed, 10/19/22 - 10:44 am

Nucleome Therapeutics

precision medicine

autoimmune diseases

autoimmune disease

Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor

Seeking Alpha

Wed, 09/21/22 - 08:01 pm

Nerviano Medical Sciences

PARP inhibitors

Merck KGaA continues expansion with $285M+ investment in 2 new projects in France and Germany

Endpoints

Fri, 09/9/22 - 11:13 am

drug manufacturing

Merck KGaA launches Asia startup scheme to locate next generation of partnerships

Fierce Biotech

Fri, 07/15/22 - 10:52 am

After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor

Fierce Biotech

Sun, 06/5/22 - 11:35 pm

clinical trials

non-small cell lung cancer

Merck KGaA Strikes $550M Deal with Proxygen in Latest Protein Degradation Deal

BioSpace

Fri, 06/3/22 - 10:29 am

protein degradation

Pages